Skip to content
10-Q

Quarterly Report

CENTESSA PHARMACEUTICALS PLC CNTA

0001847903-26-000049

← back to feed
Filed
May 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 28, 2026 154.73M sh
Shares Diluted Q1 2026 · Mar 31, 2026 153.55M sh
Shares Diluted Q1 2026 · Mar 31, 2025 133.03M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$72.22M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$57.25M
Long Term Debt Q1 2026 · Mar 31, 2026 $110.44M
Long Term Debt Q1 2026 · Dec 31, 2025 $110.1M
Short Term Investments Q1 2026 · Mar 31, 2026 $214.16M
Short Term Investments Q1 2026 · Dec 31, 2025 $233.28M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $62.43M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $61.3M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $105.16M
Stockholders Equity Q1 2026 · Mar 31, 2026 $487.35M
Stockholders Equity Q1 2026 · Dec 31, 2025 $526.86M
Stockholders Equity Q1 2026 · Mar 31, 2025 $386.25M
Stockholders Equity Q1 2026 · Dec 31, 2024 $401.55M
Current Liabilities Q1 2026 · Mar 31, 2026 $36.57M
Current Liabilities Q1 2026 · Dec 31, 2025 $42.94M
Total Liabilities Q1 2026 · Mar 31, 2026 $154.42M
Total Liabilities Q1 2026 · Dec 31, 2025 $160.63M
Current Assets Q1 2026 · Mar 31, 2026 $348.68M
Current Assets Q1 2026 · Dec 31, 2025 $367.88M
Total Assets Q1 2026 · Mar 31, 2026 $641.76M
Total Assets Q1 2026 · Dec 31, 2025 $687.5M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.52
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.20
Eps Basic Q1 2026 · Mar 31, 2026 −$0.52
Eps Basic Q1 2026 · Mar 31, 2025 −$0.20
Sga Expense Q1 2026 · Mar 31, 2026 $19.88M
Sga Expense Q1 2026 · Mar 31, 2025 $12.33M
Net Income Q1 2026 · Mar 31, 2026 −$79.24M
Net Income Q1 2026 · Mar 31, 2025 −$26.14M
Operating Income Q1 2026 · Mar 31, 2026 −$79.77M
Operating Income Q1 2026 · Mar 31, 2025 −$30.78M
Revenue Q1 2026 · Mar 31, 2026 $0
Revenue Q1 2026 · Mar 31, 2025 $15M